Company intelligence / Profile preview
Avata Biosciences
London, England, United Kingdomavatabio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
SAP021 demonstrated favorable safety/tolerability and pharmacokinetics compared to Epidiolex® in a two-part Phase I trial. The company is pursuing expedited FDA review via the de-risked US regulatory pathway with commercial launch targeted post-FDA approval (~2028).
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Synthetic cannabinoids (notably cannabidiol/CBD)Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Oxford University – partnership focused on mental health indications using their lead program.
Beyond the preview
Go deeper on Avata Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avata Biosciences.